⌕
Alkermes · ALKS · Nasdaq
Tenet 37 · Weak
Compare
$46.53−1.06%At closeTenet 37 · Weak
$46.53−0.50 (−1.06%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Alkermes (ALKS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is ALKS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 16, 2026 · 04:12 ET
Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead

Alkermes NASDAQ: ALKS is preparing for a series of clinical readouts across its orexin drug programs, with studies in sleep disorders, attention-deficit/hyperactivity disorder and fatigue expected over the next 12 months…

ALKS −1.1% todayRead at source ↗
● Business WireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present data from across its psychiatry and sleep medicine portfolios at the Neuroscience Education Institute (NEI) Fall Congress, taking plac…

ALKS −1.1% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 19:15 ETEARNINGS EXPECTED BY FEB 16
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript

Alkermes plc ( ALKS ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Blair Jackson - President, CEO & Director Todd…

ALKS −1.1% todayRead at source ↗
● MarketBeatNov 3, 2026 · 13:17 ETEARNINGS EXPECTED BY FEB 16
What Alkermes (ALKS) Said on Its Q3 Earnings Call

Alkermes NASDAQ: ALKS reported third-quarter 2026 results marked by 31% year-over-year growth in proprietary product sales, while management highlighted continued investment in its orexin development portfolio across sle…

ALKS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 16
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and t…

ALKS −1.1% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 09:16 ETEARNINGS EXPECTED BY FEB 16
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

Alkermes (ALKS) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.49 per share a year ago.…

ALKS −1.1% todayRead at source ↗
● Business WireNov 3, 2026 · 07:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Alkermes plc Reports Third Quarter 2026 Financial Results

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visi…

ALKS −1.1% todayRead at source ↗
● Defense WorldNov 3, 2026 · 03:45 ETEARNINGS EXPECTED BY FEB 16
Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast

Vericel (NASDAQ: VCEL - Get Free Report) and Alkermes (NASDAQ: ALKS - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of th…

ALKS −1.1% todayRead at source ↗
● Business WireOct 30, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants wit…

ALKS −1.1% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 14:39 ETEARNINGS EXPECTED BY FEB 16
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story

Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but decline sequentially, with…

ALKS −1.1% todayRead at source ↗
● Defense WorldOct 26, 2026 · 04:57 ETEARNINGS EXPECTED BY FEB 16
Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. trimmed its position in Alkermes plc (NASDAQ: ALKS) by 37.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C…

ALKS −1.1% todayRead at source ↗
● Business WireOct 20, 2026 · 16:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Alkermes to Report Third Quarter Financial Results on November 3, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third quarter financial resu…

ALKS −1.1% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 16
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

ALKS −1.1% todayRead at source ↗
● Defense WorldOct 20, 2026 · 03:53 ETEARNINGS EXPECTED BY FEB 16
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue lessened its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 43.6% during a recent quarter, according to its most recent 13F filing with the SEC. The institutional investor owne…

ALKS −1.1% todayRead at source ↗
● Business WireOct 13, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research S…

ALKS −1.1% todayRead at source ↗
● Zacks Investment ResearchOct 9, 2026 · 11:31 ET
4 CNS Drug Stocks Worth Watching This World Mental Health Day

AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.…

ALKS −1.1% todayRead at source ↗
● Defense WorldOct 6, 2026 · 08:14 ETEARNINGS EXPECTED BY FEB 16
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)

Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their anal…

ALKS −1.1% todayRead at source ↗
● Zacks Investment ResearchSep 30, 2026 · 14:50 ET
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?

LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.…

ALKS −1.1% todayRead at source ↗
● Seeking AlphaSep 26, 2026 · 08:48 ETEARNINGS EXPECTED BY FEB 16
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver

Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental revenue, leveraging …

ALKS −1.1% todayRead at source ↗
● Zacks Investment ResearchSep 22, 2026 · 12:16 ET
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.…

ALKS −1.1% todayRead at source ↗
● Investors Business DailySep 21, 2026 · 09:22 ET
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.…

ALKS −1.1% todayRead at source ↗
● Business WireSep 21, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company's novel, investigational orexin 2 receptor (OX2R) agon…

ALKS −1.1% todayRead at source ↗
● Business WireSep 16, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmac…

ALKS −1.1% todayRead at source ↗
● Business WireSep 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now in its ninth year, t…

ALKS −1.1% todayRead at source ↗
● Business WireAug 24, 2026 · 18:30 ET
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is…

ALKS −1.1% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA10−4.2%
UAL4+1.3%
AMZN3−3.0%

Article counts from the last market-wide feed page, across every symbol we track and not just ALKS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.